Keeping you up to date on recent developments in diagnostics, including: Improving diagnosis of prostate cancer; Assay system identifies mitochondria-targeting drugs for PD; Ovarian organoids implicate oviducts.
Two major papers on repurposed drugs for COVID-19 by researchers from Brigham and Women’s Hospital face intense skepticism from the research community, prompting the editorial boards of TheNew England Journal of Medicine and The Lancet to publish Expressions of Concern on the validity of the underlying data. Such expressions are often the first step toward an outright retraction.
Keeping you up to date on recent developments in oncology, including: Hydrogen plus gemcitabine may prove efficacious in treatment of bladder cancer; Tumor types have distinct microbiomes; Kinase helps prepare pre-metastatic niche; EZH2 has dual role; Sulfur-for-oxygen switch enables photosensitizers for cancer therapy.
In emergency situations, broad-spectrum antibiotics have their place. But their indiscriminate use has led to a resistance crisis that already kills tens of thousands of people annually in the U.S. alone.
Keeping you up to date on recent developments in cardiology, including: iPSC microtissue gives clues to heart disease; Two paths for helping patients with heart stents; COVID-19 hits stroke patients.
Keeping you up to date on recent developments in diagnostics, including: Double-contrast probe detects tiny tumors on MRI, Identifying risk of ischemic stroke, T cell aging induces broader senescence, ALK is a candidate thinness gene.
Variants in the APOE gene are the strongest genetic risk factor for developing Alzheimer’s disease (AD). Now, researchers at Rockefeller University have demonstrated that APOE variants also affected the risk of progression and metastasis as well as the response to immunotherapy, in melanoma.
Keeping you up to date on recent developments in oncology, including: Optoacoustic mesoscopy offers three-dimensional tumor imaging without biopsy; P53 loss leads to immune evasion; Treatment less toxic for Burkitt lymphoma.
Variants in the APOE gene are the strongest genetic risk factor for developing Alzheimer’s disease (AD). Now, researchers at Rockefeller University have demonstrated that APOE variants also affected the risk of progression and metastasis as well as the response to immunotherapy, in melanoma.